Crinetics Pharmaceuticals (CRNX)
(Real Time Quote from BATS)
$54.12 USD
+0.78 (1.46%)
Updated Jul 26, 2024 02:56 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRNX 54.12 +0.78(1.46%)
Will CRNX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates
Other News for CRNX
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Elevance Health (ELV) and Johnson & Johnson (JNJ)
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
Optimistic Buy Rating for Crinetics Pharmaceuticals Backed by Promising Drug Developments